SABCS Coverage: MA.27 Study Finds Exemestane and Anastrozole Comparable

Audrey Andrews
Published: Wednesday, Mar 02, 2011
Exemestane (Aromasin) was no better than anastrozole (Arimidex) at reducing cancer recurrence in postmenopausal women with hormone receptor-positive primary breast cancer, according to final data from the NCIC CTG MA.27 trial presented at the San Antonio Breast Cancer Symposium. MA.27 is the first definitive early breast cancer trial comparing a nonsteroidal and a steroidal aromatase inhibitor as adjuvant therapy. Anastrozole, the nonsteroidal aromatase inhibitor, is approved as single-agent adjuvant therapy; exemestane, the steroidal aromatase inhibitor, is approved as sequential therapy in women who have received 2 to 3 years of tamoxifen.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication